Madrigal Pharmaceuticals Inc (MDGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
68
About the Report
About the Report
Summary
Madrigal Pharmaceuticals Inc (Madrigal), formerly, Synta Pharmaceuticals Corp is a biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, MGL-3196 (orally administered), is a proprietary, liver-directed, selective thyroid hormone receptor beta, (THR-ß), agonist that can potentially be used for treating several disease with high unmet medical need. The company is developing MGL-3196 for non-alcoholic steatohepatitis (NASH) and familial hypercholesterolemia (FH). The company is also developing MGL-3745 (THR-ß agonist), a preclinical compound that has similar thyroid receptor selectivity to MGL-3196. Madrigal is also headquartered in West Conshohocken, Pennsylvania, the US.
Madrigal Pharmaceuticals Inc (MDGL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Madrigal Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Madrigal Pharma Raises USD3.37 Million in Venture Financing 12
Merger 13
Madrigal Pharma and Synta Pharma Merges 13
Licensing Agreements 15
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 15
PRCL Research Enters into Licensing Agreement with Synta Pharma 16
Equity Offering 17
Madrigal Pharma Plans to Raise USD200 Million in Public Offering of Securities 17
Madrigal Pharma Prices Public Offering of Shares for USD125 Million 18
Madrigal Pharma Plans to Raise up to USD5 Million in Public Offering of Shares 20
Madrigal Pharma Raises USD35 Million in Private Placement of Shares 21
Madrigal Pharma Raises USD6.1 Million in Public Offering of Shares 22
Synta Pharma Raises USD44.3 Million in Public Offering of Shares 23
Synta Pharma Raises USD5 Million in Private Placement Of Shares 25
Synta Pharma Completes Public Offering Of Shares For USD 60.4 Million 26
Synta Pharma Completes Private Placement Of Shares For USD 9.3 Million 28
Synta Pharma Completes Private Placement Of Common Stock For USD 60 Million 29
Synta Pharma Completes Private Placement Of Shares For USD 26 Million 31
Synta Pharma Completes Over-allotment Option For Public Offering Of Common Stock For USD 35 Million 33
Asset Transactions 35
Synta Pharma Sells its Drug Candidate, Elesclomol 35
Acquisition 36
Madrigal Pharma May Sell Itself 36
Madrigal Pharmaceuticals Inc-Key Competitors 37
Madrigal Pharmaceuticals Inc-Key Employees 38
Madrigal Pharmaceuticals Inc-Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Nov 06, 2018: Madrigal Pharmaceuticals reports 2018 third quarter 40
Aug 07, 2018: Madrigal Pharmaceuticals reports 2018 second quarter financial results and reviews key clinical achievements 42
May 08, 2018: Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements 45
Mar 13, 2018: Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196 47
Nov 09, 2017: Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results 49
Aug 10, 2017: Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results 51
May 11, 2017: Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results 53
Apr 03, 2017: Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196 54
Clinical Trials 56
May 31, 2018: Madrigal's MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial 56
Feb 08, 2018: Madrigal's MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia 58
Jan 30, 2018: Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress 2018 59
Dec 06, 2017: Madrigal's MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial 60
Oct 23, 2017: Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead ß-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting 62
Sep 19, 2017: Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia 63
Aug 01, 2017: Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH 64
May 11, 2017: Madrigal Pharmaceuticals Provides Update on lead compound MGL-3196 65
Feb 23, 2017: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68
List of Figure
List of Figures
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Madrigal Pharma Raises USD3.37 Million in Venture Financing 12
Madrigal Pharma and Synta Pharma Merges 13
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 15
PRCL Research Enters into Licensing Agreement with Synta Pharma 16
Madrigal Pharma Plans to Raise USD200 Million in Public Offering of Securities 17
Madrigal Pharma Prices Public Offering of Shares for USD125 Million 18
Madrigal Pharma Plans to Raise up to USD5 Million in Public Offering of Shares 20
Madrigal Pharma Raises USD35 Million in Private Placement of Shares 21
Madrigal Pharma Raises USD6.1 Million in Public Offering of Shares 22
Synta Pharma Raises USD44.3 Million in Public Offering of Shares 23
Synta Pharma Raises USD5 Million in Private Placement Of Shares 25
Synta Pharma Completes Public Offering Of Shares For USD 60.4 Million 26
Synta Pharma Completes Private Placement Of Shares For USD 9.3 Million 28
Synta Pharma Completes Private Placement Of Common Stock For USD 60 Million 29
Synta Pharma Completes Private Placement Of Shares For USD 26 Million 31
Synta Pharma Completes Over-allotment Option For Public Offering Of Common Stock For USD 35 Million 33
Synta Pharma Sells its Drug Candidate, Elesclomol 35
Madrigal Pharma May Sell Itself 36
Madrigal Pharmaceuticals Inc, Key Competitors 37
Madrigal Pharmaceuticals Inc, Key Employees 38
Madrigal Pharmaceuticals Inc, Subsidiaries 39
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.